Single-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. Advantages like these have generated an ever-growing demand for this technology over the years. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors.
Mainz Biomed Partners with Microba Life Sciences
Latest NewsMolecular diagnostics specialist Mainz Biomed NV has inked a research collaboration with precision microbiome firm Microba Life Sciences Inc.
DiogenX SA raises €27.5M in Series A financing
Latest NewsFrench pancreatic beta-cell modulator specialist DiogenX SA has raised €27.5m in a Series A financing led by Boehringer Ingelheim Venture Fund and Roche Venture Fund.
Immunovia AB with new CEO
AppointmentsJeff Borcherding, President of Immunovia’s US subsidiary since April 2022, has been the new Global CEO of Sweden’s Immunovia AB since the end of April.
Wacker AG expands biotech business through €100m acquisition
Latest NewsMunich-based Wacker Group has purchased all shares of the Spanish CMO ADL BioPharma from financial investor Kartesia for €100m.
BioBLU® Single-Use Bioreactors – Single-Use Simplicity
ProductsSingle-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. Advantages like these have generated an ever-growing demand for this technology over the years. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors.
Changes in the management of Abivax
AppointmentsThe French Abivax SA has had a new CEO since the beginning of May. Marc de Garidel took over the position and became interim chairman of the supervisory board.
Neogap Therapeutics AB partners with Cellerys AG
Latest NewsSwedish AI specialist Neogap Therapeutics AB will secect antigens for Cellerys AG, which wants to establish immune tolerance in a Phase II MS trial.
Conflict of interest?
OpinionIn 2016, PharmaMar filed a European marketing authorisation application for Aplidin as a treatment for patients with multiple myeloma. After the European Medicines Agency rejected the MAA twice, which was accepted in Australia with the same data, PharmaMar sued the EC. European Biotechnology spoke with PharmaMars Chairman José María Fernández Sousa-Faro.
Dutch State to sell share capital of Intravacc BV
Latest NewsThe State of the Netherlands, and the Dutch Ministry of Health, Welfare and Sport will sell all shares of vaccine maker Intravacc B.V.
Immunology expert joins ImmunOs Therapeutics
AppointmentsThe biopharmaceutical company ImmunOs Therapeutics AG has appointed Michael A. Curran, PhD, as Chairman of the Company´s Scientific Advisory Board.